| . | . | . | . | . | . | Susceptibility . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | MIC (mg/L) . | CLSI . | PK/PD . | EUCAST . | |||||||
| Antimicrobial . | n . | 50% . | 90% . | min . | max . | %S . | %I . | %R . | %S . | %S . | %I . | %R . |
| India | ||||||||||||
| AMCa | 78 | 0.03 | 0.25 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 (100) | 100b | 0.0 | 0.0 |
| azithromycin | 78 | 64 | >256 | 0.12 | >256 | NA | NA | NA | NA | NA | NA | NA |
| cefixime | 78 | 0.25 | 0.5 | 0.03 | 32 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefpodoxime | 78 | 0.03 | 0.03 | ≤0.015 | 4 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefuroxime | 78 | ≤0.015 | 0.03 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 | 100b | 0.0 | 0.0 |
| clarithromycin | 78 | 32 | >256 | 0.06 | >256 | NA | NA | NA | NA | NA | NA | NA |
| erythromycinc | 76 | 16 | >256 | 0.06 | >256 | 23.7 | 7.9 | 68.4 | NA | NA | NA | NA |
| levofloxacin | 78 | 1 | >32 | 0.5 | >32 | 79.5 | 9.0 | 11.5 | 79.5 | 55.1 | 24.4 | 20.5 |
| ofloxacin | 78 | 2 | >32 | 1 | >32 | 52.6 | 24.4 | 23.1 | NA | NA | NA | NA |
| penicillin | 78 | 0.015 | 0.03 | ≤0.015 | 0.12 | 100 | 0.0 | 0.0 | NA | 100 | 0.0 | 0.0 |
| SXT | 78 | >32 | >32 | ≤0.015 | >32 | NA | NA | NA | 33.3 | 33.3 | 0.0 | 66.7 |
| erythromycind | 78 | — | — | — | — | 21.8 | 7.7 | 70.5 | — | 21.8 | 3.8 | 74.4 |
| . | . | . | . | . | . | Susceptibility . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | MIC (mg/L) . | CLSI . | PK/PD . | EUCAST . | |||||||
| Antimicrobial . | n . | 50% . | 90% . | min . | max . | %S . | %I . | %R . | %S . | %S . | %I . | %R . |
| India | ||||||||||||
| AMCa | 78 | 0.03 | 0.25 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 (100) | 100b | 0.0 | 0.0 |
| azithromycin | 78 | 64 | >256 | 0.12 | >256 | NA | NA | NA | NA | NA | NA | NA |
| cefixime | 78 | 0.25 | 0.5 | 0.03 | 32 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefpodoxime | 78 | 0.03 | 0.03 | ≤0.015 | 4 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefuroxime | 78 | ≤0.015 | 0.03 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 | 100b | 0.0 | 0.0 |
| clarithromycin | 78 | 32 | >256 | 0.06 | >256 | NA | NA | NA | NA | NA | NA | NA |
| erythromycinc | 76 | 16 | >256 | 0.06 | >256 | 23.7 | 7.9 | 68.4 | NA | NA | NA | NA |
| levofloxacin | 78 | 1 | >32 | 0.5 | >32 | 79.5 | 9.0 | 11.5 | 79.5 | 55.1 | 24.4 | 20.5 |
| ofloxacin | 78 | 2 | >32 | 1 | >32 | 52.6 | 24.4 | 23.1 | NA | NA | NA | NA |
| penicillin | 78 | 0.015 | 0.03 | ≤0.015 | 0.12 | 100 | 0.0 | 0.0 | NA | 100 | 0.0 | 0.0 |
| SXT | 78 | >32 | >32 | ≤0.015 | >32 | NA | NA | NA | 33.3 | 33.3 | 0.0 | 66.7 |
| erythromycind | 78 | — | — | — | — | 21.8 | 7.7 | 70.5 | — | 21.8 | 3.8 | 74.4 |
min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for macrolides by EUCAST or PK/PD because Etest® breakpoints in CO2 not available); SXT, trimethoprim/sulfamethoxazole.
aPK/PD susceptibility at high dose is shown in parentheses.
bCLSI and EUCAST guidelines assumes susceptibility to amoxicillin/clavulanic acid and cephalosporins based on penicillin susceptibility.
cbioMérieux Etest® breakpoints for incubation in CO2.
dUsing S/I/R zone diameters (mm) of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).
| . | . | . | . | . | . | Susceptibility . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | MIC (mg/L) . | CLSI . | PK/PD . | EUCAST . | |||||||
| Antimicrobial . | n . | 50% . | 90% . | min . | max . | %S . | %I . | %R . | %S . | %S . | %I . | %R . |
| India | ||||||||||||
| AMCa | 78 | 0.03 | 0.25 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 (100) | 100b | 0.0 | 0.0 |
| azithromycin | 78 | 64 | >256 | 0.12 | >256 | NA | NA | NA | NA | NA | NA | NA |
| cefixime | 78 | 0.25 | 0.5 | 0.03 | 32 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefpodoxime | 78 | 0.03 | 0.03 | ≤0.015 | 4 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefuroxime | 78 | ≤0.015 | 0.03 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 | 100b | 0.0 | 0.0 |
| clarithromycin | 78 | 32 | >256 | 0.06 | >256 | NA | NA | NA | NA | NA | NA | NA |
| erythromycinc | 76 | 16 | >256 | 0.06 | >256 | 23.7 | 7.9 | 68.4 | NA | NA | NA | NA |
| levofloxacin | 78 | 1 | >32 | 0.5 | >32 | 79.5 | 9.0 | 11.5 | 79.5 | 55.1 | 24.4 | 20.5 |
| ofloxacin | 78 | 2 | >32 | 1 | >32 | 52.6 | 24.4 | 23.1 | NA | NA | NA | NA |
| penicillin | 78 | 0.015 | 0.03 | ≤0.015 | 0.12 | 100 | 0.0 | 0.0 | NA | 100 | 0.0 | 0.0 |
| SXT | 78 | >32 | >32 | ≤0.015 | >32 | NA | NA | NA | 33.3 | 33.3 | 0.0 | 66.7 |
| erythromycind | 78 | — | — | — | — | 21.8 | 7.7 | 70.5 | — | 21.8 | 3.8 | 74.4 |
| . | . | . | . | . | . | Susceptibility . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | MIC (mg/L) . | CLSI . | PK/PD . | EUCAST . | |||||||
| Antimicrobial . | n . | 50% . | 90% . | min . | max . | %S . | %I . | %R . | %S . | %S . | %I . | %R . |
| India | ||||||||||||
| AMCa | 78 | 0.03 | 0.25 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 (100) | 100b | 0.0 | 0.0 |
| azithromycin | 78 | 64 | >256 | 0.12 | >256 | NA | NA | NA | NA | NA | NA | NA |
| cefixime | 78 | 0.25 | 0.5 | 0.03 | 32 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefpodoxime | 78 | 0.03 | 0.03 | ≤0.015 | 4 | 100b | 0.0 | 0.0 | 98.7 | 100b | 0.0 | 0.0 |
| cefuroxime | 78 | ≤0.015 | 0.03 | ≤0.015 | 1 | 100b | 0.0 | 0.0 | 100 | 100b | 0.0 | 0.0 |
| clarithromycin | 78 | 32 | >256 | 0.06 | >256 | NA | NA | NA | NA | NA | NA | NA |
| erythromycinc | 76 | 16 | >256 | 0.06 | >256 | 23.7 | 7.9 | 68.4 | NA | NA | NA | NA |
| levofloxacin | 78 | 1 | >32 | 0.5 | >32 | 79.5 | 9.0 | 11.5 | 79.5 | 55.1 | 24.4 | 20.5 |
| ofloxacin | 78 | 2 | >32 | 1 | >32 | 52.6 | 24.4 | 23.1 | NA | NA | NA | NA |
| penicillin | 78 | 0.015 | 0.03 | ≤0.015 | 0.12 | 100 | 0.0 | 0.0 | NA | 100 | 0.0 | 0.0 |
| SXT | 78 | >32 | >32 | ≤0.015 | >32 | NA | NA | NA | 33.3 | 33.3 | 0.0 | 66.7 |
| erythromycind | 78 | — | — | — | — | 21.8 | 7.7 | 70.5 | — | 21.8 | 3.8 | 74.4 |
min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for macrolides by EUCAST or PK/PD because Etest® breakpoints in CO2 not available); SXT, trimethoprim/sulfamethoxazole.
aPK/PD susceptibility at high dose is shown in parentheses.
bCLSI and EUCAST guidelines assumes susceptibility to amoxicillin/clavulanic acid and cephalosporins based on penicillin susceptibility.
cbioMérieux Etest® breakpoints for incubation in CO2.
dUsing S/I/R zone diameters (mm) of CLSI (≤15/16–20/≥21) and EUCAST (≤18/19–21/≥22).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
